Estimation of Treatment Eligible Patients With Transthyretin Cardiac Amyloidosis Within a Health Plan

Copies of this presentation and associated educational materials obtained through Quick Response (QR) Code are for personal use only and may not be reproduced without permission from ISPOR, the authors of this poster, and the sponsor of the study (BridgeBio Pharma, Inc.)